DAVENPORT & Co LLC Sells 1,857 Shares of IDEXX Laboratories, Inc. $IDXX

DAVENPORT & Co LLC decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 35.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,333 shares of the company’s stock after selling 1,857 shares during the quarter. DAVENPORT & Co LLC’s holdings in IDEXX Laboratories were worth $2,255,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of IDXX. Virtus Advisers LLC bought a new stake in IDEXX Laboratories during the third quarter valued at about $26,000. Park Place Capital Corp bought a new position in shares of IDEXX Laboratories in the fourth quarter worth about $29,000. WealthCollab LLC purchased a new stake in shares of IDEXX Laboratories during the second quarter worth about $30,000. J.Safra Asset Management Corp purchased a new stake in shares of IDEXX Laboratories during the third quarter worth about $31,000. Finally, Armstrong Advisory Group Inc. raised its stake in IDEXX Laboratories by 55.9% during the 3rd quarter. Armstrong Advisory Group Inc. now owns 53 shares of the company’s stock valued at $34,000 after purchasing an additional 19 shares during the period. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

NASDAQ:IDXX opened at $558.32 on Friday. The business’s 50-day moving average is $631.32 and its 200 day moving average is $661.91. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $769.98. The company has a market capitalization of $44.40 billion, a P/E ratio of 42.72, a P/E/G ratio of 3.39 and a beta of 1.66. The company has a current ratio of 1.23, a quick ratio of 0.90 and a debt-to-equity ratio of 0.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings results on Monday, February 2nd. The company reported $3.08 earnings per share for the quarter, beating the consensus estimate of $2.93 by $0.15. The business had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.53 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. On average, equities research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wall Street Zen cut IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Piper Sandler cut their price objective on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. UBS Group reduced their price objective on shares of IDEXX Laboratories from $750.00 to $730.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 3rd. Weiss Ratings downgraded shares of IDEXX Laboratories from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, January 29th. Finally, BTIG Research dropped their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a research report on Tuesday, February 3rd. Seven analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $783.33.

Insider Transactions at IDEXX Laboratories

In related news, EVP Nimrata Hunt sold 2,693 shares of the business’s stock in a transaction on Thursday, February 26th. The shares were sold at an average price of $661.54, for a total value of $1,781,527.22. Following the sale, the executive vice president owned 19,899 shares in the company, valued at approximately $13,163,984.46. The trade was a 11.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael G. Erickson sold 5,371 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $627.38, for a total transaction of $3,369,657.98. Following the sale, the executive vice president directly owned 12,693 shares in the company, valued at approximately $7,963,334.34. The trade was a 29.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 45,957 shares of company stock valued at $29,862,109 in the last 90 days. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.